Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.90

+3.7%

Dec 22 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (3402)	4/11/2001 9:14:08 AM
From: Jibacoa	Read Replies (2) of 52153

GERN: 2,400 traded at 11.80 in P.M. MENLO PARK, Calif.--(BW HealthWire)--April 11, 2001--Geron Corporation (Nasdaq:GERN - news) announced today the publication of research demonstrating that blocking telomerase production in breast cancer cells leads to increased sensitivity to the widely used breast cancer chemotherapeutic agent doxorubicin. This study further supports Geron's therapeutic program in telomerase inhibition for cancer and provides additional evidence that a telomerase inhibitor could be synergistic with existing anti-cancer drugs. Chart: siliconinvestor.com siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next